Fuzuloparib

Phase 3Small molecule

JJiangsu HengRui Medicine Co., Ltd.

Fuzuloparib is one of 81 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Ovarian CancerNot yet recruiting

Prostate CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

20 2

Zoladex

TTerSera Therapeutics LLC

Phase 3

35 3

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 4

Docetaxel /m²

AstraZeneca

Phase 3

2 5

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 6

Fuzuloparib

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 7

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

5 8

Trexall

Jazz Pharmaceuticals

Preclinical

—9

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Prostate Cancer

NCT04691804

Q4 2027

Phase 2Recruiting

Ovarian Cancer

NCT05753826

Q4 2030

Phase 2Not yet recruiting

Ovarian Cancer

NCT07355010

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Not yet recruiting·QQinglei Gao·Phase 2·NCT07355010·104 enrolled

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Recruiting·FFujian Cancer Hospital·Phase 2·NCT05753826·37 enrolled

Prostate Cancer1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04691804·496 enrolled

Adult Subject1 trial

A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT05440006·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Fuzuloparib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fuzuloparib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fuzuloparib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

Fuzuloparib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2030

Trials by Indication[1]

Ovarian Cancer2 trials

Prostate Cancer1 trial

Adult Subject1 trial

References

Drug Info

Quick Facts

Related News